Identifying locally actionable strategies to increase participant acceptability and feasibility to participate in Phase I cancer clinical trials

Abstract Background Recruitment of cancer clinical trial (CCT) participants, especially participants representing the diversity of the US population, is necessary to create successful medications and a continual challenge. These challenges are amplified in Phase I cancer trials that focus on evaluat...

Full description

Saved in:
Bibliographic Details
Main Authors: Stephanie A. S. Staras (Author), Easton N. Wollney (Author), Lisa E. Emerson (Author), Natalie Silver (Author), Peter T. Dziegielewski (Author), Marta D. Hansen (Author), Gabriela Sanchez (Author), Dalila D'Ingeo (Author), Versie Johnson‐Mallard (Author), Rolf Renne (Author), Kristianna Fredenburg (Author), Michael Gutter (Author), Kendra Zamojski (Author), Carla Vandeweerd (Author), Carma L. Bylund (Author)
Format: Book
Published: Wiley, 2024-02-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_70db8560562a4efd9138939a6f3b42a7
042 |a dc 
100 1 0 |a Stephanie A. S. Staras  |e author 
700 1 0 |a Easton N. Wollney  |e author 
700 1 0 |a Lisa E. Emerson  |e author 
700 1 0 |a Natalie Silver  |e author 
700 1 0 |a Peter T. Dziegielewski  |e author 
700 1 0 |a Marta D. Hansen  |e author 
700 1 0 |a Gabriela Sanchez  |e author 
700 1 0 |a Dalila D'Ingeo  |e author 
700 1 0 |a Versie Johnson‐Mallard  |e author 
700 1 0 |a Rolf Renne  |e author 
700 1 0 |a Kristianna Fredenburg  |e author 
700 1 0 |a Michael Gutter  |e author 
700 1 0 |a Kendra Zamojski  |e author 
700 1 0 |a Carla Vandeweerd  |e author 
700 1 0 |a Carma L. Bylund  |e author 
245 0 0 |a Identifying locally actionable strategies to increase participant acceptability and feasibility to participate in Phase I cancer clinical trials 
260 |b Wiley,   |c 2024-02-01T00:00:00Z. 
500 |a 1369-7625 
500 |a 1369-6513 
500 |a 10.1111/hex.13920 
520 |a Abstract Background Recruitment of cancer clinical trial (CCT) participants, especially participants representing the diversity of the US population, is necessary to create successful medications and a continual challenge. These challenges are amplified in Phase I cancer trials that focus on evaluating the safety of new treatments and are the gateway to treatment development. In preparation for recruitment to a Phase I recurrent head and neck cancer (HNC) trial, we assessed perceived barriers to participation or referral and suggestions for recruitment among people with HNC and community physicians (oncologist, otolaryngologist or surgeon). Methods Between December 2020 and February 2022, we conducted a qualitative needs assessment via semistructured interviews with a race and ethnicity‐stratified sample of people with HNC (n = 30: 12 non‐Hispanic White, 9 non‐Hispanic African American, 8 Hispanic and 1 non‐Hispanic Pacific Islander) and community physicians (n = 16) within the University of Florida Health Cancer Center catchment area. Interviews were analyzed using a qualitative content analysis approach to describe perspectives and identify relevant themes. Results People with HNC reported thematic barriers included: concerns about side effects, safety and efficacy; lack of knowledge and systemic and environmental obstacles. Physicians identified thematic barriers of limited physician knowledge; clinic and physician barriers and structural barriers. People with HNC and physicians recommended themes included: improved patient education, dissemination of trial information and interpersonal communication between community physicians and CCT staff. Conclusions The themes identified by people with HNC and community physicians are consistent with research efforts and recommendations on how to increase the participation of people from minoritized populations in CCTs. This community needs assessment provides direction on the selection of strategies to increase CCT participation and referral. Patient or Public Contribution This study focused on people with HNC and community physicians' lived experience and their interpretations of how they would consider a future Phase I clinical trial. In addition to our qualitative data reflecting community voices, a community member reviewed the draft interview guide before data collection and both people with HNC and physicians aided interpretation of the findings. 
546 |a EN 
690 |a cancer 
690 |a community oncology 
690 |a patient education 
690 |a Phase I 
690 |a underrepresentation 
690 |a Medicine (General) 
690 |a R5-920 
690 |a Public aspects of medicine 
690 |a RA1-1270 
655 7 |a article  |2 local 
786 0 |n Health Expectations, Vol 27, Iss 1, Pp n/a-n/a (2024) 
787 0 |n https://doi.org/10.1111/hex.13920 
787 0 |n https://doaj.org/toc/1369-6513 
787 0 |n https://doaj.org/toc/1369-7625 
856 4 1 |u https://doaj.org/article/70db8560562a4efd9138939a6f3b42a7  |z Connect to this object online.